Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. IBM
10. HOOD

Go back to Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan

Viracta Therapeutics (VIRX) PT Lowered to $4 at RBC Capital

August 15, 2024 6:16 AM EDT

RBC Capital analyst Kennen MacKay lowered the price target on Viracta Therapeutics (NASDAQ: VIRX) to $4.00 (from $6.00) while maintaining a Outperform rating.

The analyst comments "VIRX shared new NAVAL-1 data (Stage 1+2) that suggest stronger efficacy of Nana-val in 2L EBV+ PTCL (vs. 2L+,... More